References
- Elens L , Van GelderT , HesselinkDA , HaufroidV , Van SchaikRH . CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy . Pharmacogenomics14 ( 1 ), 47 – 62 ( 2013 ).
- Haufroid V , WallemacqP , VankerckhoveVet al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study . Am. J. Transplant.6 ( 11 ), 2706 – 2713 ( 2006 ).
- Hesselink DA , BouamarR , ElensL , Van SchaikRH , Van GelderT . The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation . Clin. Pharmacokinet.53 ( 2 ), 123 – 139 ( 2014 ).
- Birdwell KA , DeckerB , BarbarinoJMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing . Clin. Pharmacol. Ther.98 ( 1 ), 19 – 24 ( 2015 ).
- Andreu F , ColomH , ElensLet al. A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach . Clin. Pharmacokinet. doi:10.1007/s40262-016-0491-0493 ( 2017 ) ( Epub ahead of print ).
- Elens L , CapronA , Van SchaikRHet al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines . Ther. Drug Monitor.35 ( 5 ), 608 – 616 ( 2013 ).
- Elens L , HesselinkDA , Van SchaikRH , Van GelderT . The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations . Br. J. Clin. Pharmacol.75 ( 6 ), 1545 – 1547 ( 2013 ).
- Elens L , Van SchaikRH , PaninNet al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients . Pharmacogenomics12 ( 10 ), 1383 – 1396 ( 2011 ).
- Wang D , GuoY , WrightonSA , CookeGE , SadeeW . Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs . Pharmacogenomics J.11 ( 4 ), 274 – 286 ( 2011 ).
- Wang D , SadeeW . CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing . Pharmacogenet. Genomics26 ( 1 ), 40 – 43 ( 2016 ).
- Woillard J , MouradM , NeelyMet al. Tacrolimus updated guidelines through population-based pharmacokinetics modeling: how to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation . Front. Pharmacol. ( 2017 ) ( In Press ).
- De Meyer M , HaufroidV , KanaanNet al. Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study . Pharmacogenomics17 ( 9 ), 1019 – 1027 ( 2016 ).
- Capron A , MouradM , De MeyerMet al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation . Pharmacogenomics11 ( 5 ), 703 – 714 ( 2010 ).
- Ensemble . www.ensemble.org .
- De Jonge H , MetalidisC , NaesensM , LambrechtsD , KuypersDR . The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients . Pharmacogenomics12 ( 9 ), 1281 – 1291 ( 2011 ).
- Elens L , HesselinkDA , BouamarRet al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients . Ther. Drug Monitor.36 ( 1 ), 71 – 79 ( 2014 ).